| Name | Title | Contact Details |
|---|
Bird Products Corporation is a Palm Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genetic Technologies, Inc. is an independent, full service and multi-accredited DNA forensic science company focusing primarily on the testing and evaluation of forensic evidence as it relates to human identification. Established in 1998, Genetic Technologies, Inc. serves a rapidly growing nationwide and worldwide customer base of private citizens, investigators, law enforcement agencies, public defenders, criminal defense attorneys, and prosecutors. We offer our clients access to a broad range of forensic biology technologies—specializing in DNA analysis, (Autosomal and Y-STRs), touch DNA (Low Copy Analysis), Crime Scene Investigation (CSI), serology, and expert witness & consulting services for civil investigations / criminal prosecution & defense. Our forensic division has played a pivotal role in a hundreds of high profile criminal cases with our civil and relatedness divisions assisting clients in thousands of immigration / relatedness DNA tests including a wide spectrum of infidelity scenarios. Our seasoned staff of expert scientists utilizes the most advanced methodologies available to detect and test DNA from many sources. We offer fast, accurate and personalized service for each of our customers, including consulting and expert witness services in conjunction with forensic testing. Genetic Technologies, Inc. is a leader in the Forensic Science and Human Identification Industry and provides specialized software to the eDNA Consortium. eDNA is a software developed by Genetic Technologies, Inc. which is used by many facilities in the Human Identification Industry.
Sandra Heath and Associates is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Johns Lutheran Community is a senior living community in Albert Lea, MN that provides short term care, skilled nursing care, independent living, assisted living, and memory care homes.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.